Interleukin (IL)-18 is a pro-inflammatory cytokine that is proposed to be involved in physiological as well as pathological conditions in the adult brain. IL-18 acts through a heterodimer receptor comprised of a subunit alpha (IL-18Ra) required for binding, and a subunit beta (IL-18Rb) necessary for activation of signal transduction. We recently demonstrated that the canonical alpha binding chain, and its putative decoy isoform, are expressed in the mouse central nervous system (CNS) suggesting that IL-18 may act on the brain by directly binding its receptor.
a b s t r a c t
Interleukin (IL)-18 is a pro-inflammatory cytokine that is proposed to be involved in physiological as well as pathological conditions in the adult brain. IL-18 acts through a heterodimer receptor comprised of a subunit alpha (IL-18Ra) required for binding, and a subunit beta (IL-18Rb) necessary for activation of signal transduction. We recently demonstrated that the canonical alpha binding chain, and its putative decoy isoform, are expressed in the mouse central nervous system (CNS) suggesting that IL-18 may act on the brain by directly binding its receptor.
Considering that the co-expression of the beta chain seems to be required to generate a functional receptor and, a short variant of this chain has been described in rat and human brain, in this study we have extended our investigation to IL-18Rb in mouse.
Using a multi-methodological approach we found that: (1) a short splice variant of IL-18Rb was expressed in the CNS even if at lower levels compared to the full-length IL-18Rb variants, (2) the canonical IL-18Rb is expressed in the CNS particularly in areas and nuclei belonging to the limbic system as previously observed for IL-18Ra and finally (3) we have also demonstrated that both IL-18Rb isoforms are up-regulated in different brain areas three hours after a single lipopolysaccharide (LPS) injection suggesting that IL-18Rb in the CNS might be involved in mediating the endocrine and behavioral effects of LPS.
Our data highlight the considerable complexity of the IL-18 regulation activity in the mouse brain and further support an important central role for IL-18.
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Introduction
Interleukin (IL)-18 is a pro-inflammatory cytokine with a pivotal role in innate as well as adaptive immunity (Okamura et al., 1998; Takeda et al., 1998) . Several studies found that IL-18 is also produced and is biologically active in the CNS where it is proposed to participate in local inflammatory reactions but also to modulate autonomic functions and the sickness behavior (recently reviewed in Alboni et al., 2010 ). Yet, its mode of central action remains to be elucidated. IL-18 acts on cells of the immune system through binding to its heterodimer receptor (IL-18R) belonging to the interleukin 1 receptor/Toll like receptor superfamily. IL-18R consists of one ligand binding chain (IL-18Ra, also known as IL-18RI, IL-1Rrp or IL-1R5) and an accessory protein IL-18Rb, also known as IL-18RII, IL18RAcP or IL-1R7 (Hoshino et al., 1999; Torigoe et al., 1997) essential for signal transduction (Sergi and Penttila, 2004) . We recently demonstrated that the canonical a chain of the IL-18R (that we arbitrarily named IL-18Ra type I) is widely expressed in neurons throughout the mouse CNS (Alboni et al., 2009) . Moreover, we demonstrate the in vivo expression in the mouse brain of a short transcript for the a chain (arbitrarily named IL-18Ra type II) lacking the intracellular Toll/IL-1 receptor (TIR) domain is required for IL-18 signaling and is thus proposed to be a decoy receptor (Alboni et al., 2009 ). Together, these findings provided evidence for a possible direct action of IL-18 on neurons and suggest that its activity may be modulated by regulating the levels of the decoy isoform.
To further investigate this possibility and the biology of central IL-18 we extended our studies to determine the central distribution of the IL-18Rb subunit that is necessary to activate IL-18 signaling
